Quiver Bioscience Appoints Graham Dempsey, PhD as Chief Executive Officer to Lead Scaling of AI-Driven CNS Platform and Advance Lead Program into the Clinic
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Quiver Bioscience ('Quiver'), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, announced the appointment of co-founder Graham Dempsey, PhD as Chief Executive Officer. Dr. Dempsey assumes the CEO role after more than a decade of scientific and operational leadership at Quiver, most recently serving as Quiver's Chief Scientific Officer, directing the planning and execution of all scientific, medical, engineering and AI/machine learning activities at the company. This appointment comes as Quiver aims to advance its lead program into the clinic, an antisense oligonucleotide (ASO) targeting Na v 1.7 for the treatment of chronic pain, while scaling its CNS-focused AI-driven drug discovery platform to accelerate a portfolio of therapeutic programs. Paul Roma, Quiver co-founder and interim CEO will transition to Chairman of the Board of Directors.
'We're excited by the potential of our genetic medicine strategy and platform to unlock this important target towards creating a transformative product for patients suffering from chronic neuropathic pain," said Dr. Dempsey
Share
Dr. Dempsey has successfully led the development and rapid evolution of the company's technology platforms since the company's inception, as well as its first small molecule and antisense oligonucleotide therapeutic programs, resulting in several foundational patents and peer-reviewed publications. He has also led more than a dozen pharma collaborations and the execution of several grants from non-dilutive funding sources such as the NIH SBIR Programs and CNS Foundations. Dr. Dempsey holds a B.A. in biochemistry (Roy and Diana Vagelos Scholar) and biophysics from the University of Pennsylvania and a Ph.D. in biophysics from Harvard Medical School, where he co-invented novel fluorescence-based imaging platforms for investigating biological systems and was part of the team that developed the super-resolution imaging technique called stochastic optical reconstruction microscopy (STORM) that was subsequently commercialized by Nikon Instruments. Dr. Dempsey serves on the Scientific Advisory Board of the Dan Lewis Foundation for Brain Regeneration Research and the editorial board of Molecular Therapy Nucleic Acids.
Under Dr. Dempsey's leadership, Quiver will advance their lead asset, an ASO targeting the genetically validated pain target Na v 1.7, a voltage gated sodium channel implicated in several neuropathic pain disorders, through IND and early clinical studies. 'Despite the longstanding promise of Nav1.7 as a target for pain, it has remained elusive for drug developers. We're excited by the potential of our genetic medicine strategy and platform to unlock this important target towards creating a transformative product for patients suffering from chronic neuropathic pain,' said Dr. Dempsey. Quiver's Na v 1.7 ASO is expected to deliver durable relief for chronic pain while overcoming limitations of other Na v -targeted small molecules currently under development and recently approved. Quiver's strong data package demonstrates the efficacy of Na v 1.7 ASOs in rescuing pain phenotypes in in vitro and in vivo models with a favorable CNS tolerability profile. The ASO program is approaching development candidate selection in 2025 and is expected to begin critical IND enabling studies shortly thereafter.
Quiver is also scaling their human-centric AI-driven novel CNS drug discovery platform with in silico models of target, efficacy and toxicity prediction, and is further bolstering a pipeline of fast-follower programs in pain, neurodevelopmental disorders, and other diseases of the CNS including the advancement of its UBE3A -targeting ASO for the neurodevelopmental disorder, chromosome 15q duplication syndrome (Dup15q) to IND. The company will be attending the BIO International Convention in Boston this week to showcase their programs and platform.
About Quiver Bioscience
Quiver Bioscience is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single-cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map via our "Genomic Positioning System." Our approach integrates cutting-edge scalable human models, state-of-the-art technology and proprietary engineering, and learning and surrogate AI/ML models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients. For more information, including partnerships and publications describing application of Quiver's GPS to drug discovery, visit www.quiverbioscience.com or follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, Successfully Deploys 68 th Electron Mission
MAHIA, New Zealand--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the Company as it continues to deliver dedicated, repeatable and reliable access to space for satellite operators. The 'Symphony In The Stars' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on June 28 th (7:08 p.m./07:08 UTC) to deploy a single spacecraft to a 650km circular Earth orbit. The mission was the first of two dedicated launches for the new customer on Electron booked less than four months ago, with a second mission scheduled before the end of 2025. Rocket Lab has now completed four launches in June for commercial satellite constellation operators, underscoring Electron's consistent performance and rapid deployment capabilities as the world's leading small launcher: the 'Full Stream Ahead' mission on June 3 rd; 'The Mountain God Guards' mission on June 11 th; 'Get The Hawk Outta Here' launched on June 26 th UTC, and today's 'Symphony In The Stars' mission. Rocket Lab Founder and CEO, Sir Peter Beck, says: 'Electron has demonstrated once again that it is the gold standard for responsive and reliable space access for small satellites. The future of space is built on proven performance, and Electron continues to deliver against a stacked launch manifest this year. Congratulations to the team on achieving its fastest launch turnaround yet between two missions from Launch Complex 1. This launch was also a quick-turn mission to meet our customer's mission requirements, and we're looking forward to doing it again later this year.' 'Symphony In The Stars' was Rocket Lab's tenth Electron mission of 2025 and its 68th launch overall. With 100% mission success so far this year, Electron continues to deliver reliable deployment amid an increasing launch cadence and rapid contract-to-launch timelines. Launch images: About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Business Wire
2 days ago
- Business Wire
KBRA Releases Research – Potential OBBBA Implications for Litigation Finance ABS
NEW YORK--(BUSINESS WIRE)--KBRA releases research examining the potential implications for litigation finance ABS stemming from proposed measures under the Tackling Predatory Litigation Funding Act (TPLFA), which is currently included in the U.S. Senate's One Big Beautiful Bill Act (OBBBA). Litigation finance has a long history and, in recent years, has established itself as a niche segment in the asset-backed securities (ABS) market. However, the TPLFA could significantly alter the economics of this evolving structured finance asset class, as it proposes substantial new taxes on profits from third-party litigation funding. Litigation finance ABS transactions, which are typically backed by nonrecourse advances to plaintiffs in personal injury and other civil cases, could face meaningful structural and liquidity challenges if the legislation is enacted. Click here to view the report. Related Publication Litigation Finance ABS: Not Settling for Less About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1010181
Business Wire
2 days ago
- Business Wire
Informa TechTarget to Announce 2025 First Quarter Financial Results on July 1, 2025
NEWTON, Mass.--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT) ('Informa TechTarget' or the 'Company'), a leading growth accelerator for the B2B Technology sector, today announced that it plans to release its Q1 2025 financial results for the three months ended March 31, 2025 after the market closes on Tuesday, July 1, 2025. The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 5:00 p.m. Eastern Time on that day to discuss the Company's financial results and outlook. The Q1 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at Conference Call Dial-In Information: United States (Toll Free): 1-833-470-1428 United States: 1-404-975-4839 United Kingdom (Toll Free): +44 808 189 6484 United Kingdom: +44 20 8068 2558 Global Dial-in Numbers Access code: 557186 Please access the call at least 10 minutes prior to the time the conference is set to begin. Please ask to be joined into the Informa TechTarget call. Conference Call Webcast Information: This webcast can be accessed via Informa TechTarget's website at Conference Call Replay Information: A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through July 31, 2025 at 11:59 p.m. ET. To hear the replay: United States (Toll Free): 1-866-813-9403 United States: 1-929-458-6194 Access Code: 670569 A web version will also be available for replay during the same period on Informa TechTarget's website at About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners.
